CYP4X1 Expression Is Associated with Metastasis and Poor Prognosis in Patients with Colorectal Cancer

Globally, the mortality rate of colorectal cancer (CRC) remains high. Despite the development of various treatments, such as targeted therapy and immunotherapy, colorectal cancer continues to be a serious health issue worldwide. Identifying new biomarkers is essential for improving prognosis and tailoring targeted therapies for CRC. This study aims to elucidate the role of <i>CYP4X1</i> in CRC and its association with patient survival and clinicopathological parameters. Using TCGA databases like GENT2, UALCAN, and GEPIA, we analyzed <i>CYP4X1</i> expression in CRC and normal tissues. Our analysis revealed a significant increase in <i>CYP4X1</i> expression in CRC tissues compared to normal tissues. And <i>CYP4X1</i> high expression was strongly associated with advanced TNM stage, poor tumor differentiation, deeper invasion, and lymph node metastasis. Kaplan-Meier analysis revealed that high <i>CYP4X1</i> expression correlated with shorter survival times. To investigate the relationship between <i>CYP4X1</i> expression and colon cancer, WST-1, Transwell, and colony formation assays were performed using colon cancer cells with siRNA-mediated <i>CYP4X1</i> downregulation. <i>CYP4X1</i> downregulation significantly inhibited cell proliferation, invasion, migration, and colony formation in vitro. Furthermore, the tumor-forming ability in mice injected with cell lines where <i>CYP4X1</i> expression was suppressed decreased. In conclusion, <i>CYP4X1</i> overexpression is closely linked to CRC progression as an independent prognostic marker and potential therapeutic target.